| Field | Specification |
|---|---|
| Mfr No | |
| Clonality | |
| Host | |
| Immunogen | E.coli-derived human MICAL3 recombinant protein (Position: K458-L1592) was used as the immunogen for the MICAL3 antibody. |
| Isotype | |
| Product Type | |
| Purity | |
| Reactivity | |
| Storage | |
| Target | |
| UniProt # |
Overview
MICAL3 Antibody / Molecule interacting with CasL protein 3 is a anti-MICAL3 Rabbit antibody Polyclonal (rabbit origin) supplied in Lyophilized format. Recommended for workflows such as Western blot (WB), Flow cytometry (FACS), ELISA with listed reactivity in Human, Mouse, Rat.
Key elements and design rationale
- Target: MICAL3
- Antibody details: Rabbit, Polyclonal (rabbit origin), isotype Rabbit IgG
- Format: Lyophilized
- Applications (as listed): WB, FACS, ELISA
Biological background
MICAL3 catalyzes F-actin oxidation, leading to filament disassembly and cytoskeletal remodeling required for vesicle fusion. It interacts with Rab8A and Rab13, forming complexes that regulate polarized exocytosis and membrane trafficking in epithelial cells. MICAL3 is localized to vesicular membranes and actin-rich regions of the cytoplasm, where it coordinates actin depolymerization and vesicle release. Its enzymatic activity is dependent on flavin adenine dinucleotide (FAD) and modulates actin dynamics through redox reactions on specific methionine residues.
The MICAL3 antibody is used in cell biology, neurobiology, and membrane trafficking research to study cytoskeletal regulation and exocytosis. Western blot analysis identifies a 230 kilodalton band corresponding to MICAL3, while immunofluorescence reveals punctate cytoplasmic staining in vesicle-associated regions. This antibody enables investigation of actin redox control, vesicle tethering, and neuronal growth cone dynamics.
MICAL3 has been implicated in axonal transport, endocytosis, and cancer cell migration. Its deregulation may contribute to disorders involving vesicle trafficking or cytoskeletal disorganization. The MICAL3 antibody provides a validated tool for studying redox-regulated actin remodeling and membrane dynamics.
Research relevance and current trends
- Connecting protein-level changes to phenotype using orthogonal readouts (genetic perturbation, transcriptomics, imaging).
- Considering isoforms and post-translational regulation when interpreting protein-level changes.
- Comparing results across species and model systems with matched controls.
Common research applications
- Western blotting: compare relative abundance and activation-state changes across conditions.
- Flow cytometry: quantify target-positive populations and signal shifts at single-cell resolution.
- ELISA: support antibody-based quantification in assay formats where applicable.
Interpret changes in signal alongside appropriate controls and, when relevant, in parallel with total-protein or pathway readouts.
Notes for experimental interpretation
- Signal can reflect expression level, isoform composition, and post-translational state; interpret results in the context of your model system and stimuli.
- Species differences and sample matrices can influence epitope recognition; prioritize matched controls and orthogonal confirmation when feasible.
Antibody notes: Polyclonal antibodies recognize multiple epitopes, which can broaden the epitope footprint and may increase sensitivity in some contexts.
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
